Zevra Therapeutics vs Zymeworks
Zevra Therapeutics reported revenue of $106 million in fiscal 2025, about the same as Zymeworks' $106 million in fiscal 2025. Zevra Therapeutics' revenue grew 350.9% in its latest year, and Zymeworks' grew 38.9%. Zevra Therapeutics had an operating margin of -59.1%, against -87.3% at Zymeworks. Free cash flow was −$2 million at Zevra Therapeutics and −$35 million at Zymeworks.
Side by side
| Zevra Therapeutics | Zymeworks | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $106M | $106M |
| Revenue growth | 350.9% | 38.9% |
| Revenue growth a year, last 5 years | 51.6% | 22.1% |
| Gross margin | — | — |
| Operating margin | −59.1% | −87.3% |
| Net margin | 78.2% | −76.6% |
| Free cash flow | −$2M | −$35M |
| Free cash flow margin | −2.3% | −32.6% |
| Return on capital | −218.8% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $42M |
| Change in diluted share count | 23.8% | −0.6% |
| Last close | $9.08 | $26.24 |
| P/E at the last close | 7.6× | 50.5× |
| Insider trades, last 12 months | — | sold $4.7 million |
| Piotroski F-score | 5 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Zevra TherapeuticsZymeworks
Operating margin
Percent of revenue
Zevra TherapeuticsZymeworks
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Zevra TherapeuticsZymeworks
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Zevra Therapeutics and Zymeworks pages.